- The Phase 1b/2 OrigAMI-1 study evaluates amivantamab-vmjw with FOLFOX or FOLFIRI in RAS/BRAF wild-type metastatic colorectal cancer.
- Results were presented at the 2026 ASCO GI Symposium.
- Colorectal cancer is the third most diagnosed cancer globally, with rising incidence in people under 50.
- MET alterations often cause resistance to EGFR inhibition, necessitating new dual-targeting approaches.
Study Overview
The Phase 1b/2 OrigAMI-1 study investigates amivantamab-vmjw, a bispecific antibody targeting EGFR and MET, combined with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.
Promising Results
The study shows encouraging anti-tumor activity, durable responses, and low treatment-related discontinuation rates, supporting further investigation in ongoing Phase 3 studies for first- and second-line colorectal cancer.
Presentation and Context
Results were presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Colorectal cancer ranks as the third most commonly diagnosed cancer worldwide, with increasing incidence in individuals under 50.
Challenges and Opportunities
More than half of colorectal cancer patients develop metastatic disease, often with liver involvement. Resistance to current first-line therapies develops early, limiting patient benefit. MET alterations frequently cause resistance to EGFR inhibition, highlighting the need for new dual-targeting approaches.
